Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]Ensartinib ADME Study in Healthy Chinese Males
NCT03804541Phase 1Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Primary endpoints: Radioactivity concentration of each plasma sample, Radioactivity concentration of each urine samples and 2 more. Status: unknown.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03804541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03804541.